For the first clinical trial of ABCB5+ MSCs, the cells were derived from small skin biopsies of the patients and expanded ex vivo, before being topically applied onto chronic, standard therapy-refractory venous ulcers (CVUs) [39]. This evidence concerns the gene ABCB5 and varicose ulcer.